<SEC-DOCUMENT>0001144204-17-054893.txt : 20171213
<SEC-HEADER>0001144204-17-054893.hdr.sgml : 20171213
<ACCEPTANCE-DATETIME>20171030172740
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-17-054893
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20171030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-839-5200

	MAIL ADDRESS:	
		STREET 1:		700 NORTH BRAND BLVD.,
		STREET 2:		SUITE 1400
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Boston&nbsp;&nbsp;&nbsp;Brussels&nbsp;&nbsp;&nbsp;Chicago&nbsp;&nbsp;&nbsp;Dallas&nbsp;&nbsp;&nbsp;D&uuml;sseldorf&nbsp;&nbsp;&nbsp;Frankfurt&nbsp;&nbsp;&nbsp;Houston&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;Los
        Angeles&nbsp;&nbsp;&nbsp;Miami</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 30%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark J. Mihanovic</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Milan&nbsp;&nbsp;&nbsp;Munich&nbsp;&nbsp;&nbsp;New
        York&nbsp;&nbsp;&nbsp;Orange County&nbsp;&nbsp;&nbsp;Paris&nbsp;&nbsp;&nbsp;Rome&nbsp;&nbsp;&nbsp;Seoul&nbsp;&nbsp;&nbsp;Silicon
        Valley&nbsp;&nbsp;&nbsp;Washington, D.C.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attorney at Law</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">mmihanovic@mwe.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 8pt">Strategic alliance with MWE China Law
    Offices (Shanghai)</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">+1 650 815 7438</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>VIA EDGAR</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Attention:</TD><TD>Kim McManus<BR>
Senior Counsel</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Re:</TD><TD>Apollo Medical Holdings, Inc.<BR>
Registration Statement on Form&nbsp;S-4<BR>
Filed August 11, 2017<BR>
File No.&nbsp;333-219898</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Ms.&nbsp;McManus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of our client,
Apollo Medical Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), we hereby provide responses to comments
(the &ldquo;<U>Comments</U>&rdquo;) of the Staff (the &ldquo;<U>Staff</U>&rdquo;) of the Securities and Exchange Commission (the
&ldquo;<U>Commission</U>&rdquo;) issued in its letter dated September 7, 2017 (the &ldquo;<U>Letter</U>&rdquo;) regarding the Company&rsquo;s
above-referenced Registration Statement on Form&nbsp;S-4 (the &ldquo;<U>Registration Statement</U>&rdquo;).&nbsp; Contemporaneous
with this filing, the Company is filing on the EDGAR system an Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-4
(&ldquo;<U>Amendment No. 1</U>&rdquo;) reflecting the responses of the Company below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
responses are numbered to correspond to the Comments as numbered in the Letter.&nbsp; For your convenience, each of the Comments
contained in the Letter have been restated in bold below in their entirety, with the Company&rsquo;s corresponding response set
forth immediately under such comment.&nbsp; In the responses below, page&nbsp;number references are to Amendment No. 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Please note the updating requirements for the financial statements and related disclosures. Reference
is made to Item 14(e) and Item 17(b)(8) of Form S-4.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company revised the financial statements and related disclosures in Amendment No.
1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">We note that you amended the Merger Agreement as of March 30, 2017, in connection with the Securities
Purchase Agreement entered into with Alliance. Please discuss ApolloMed&rsquo;s and NMM&rsquo;s determination not to request an
updated fairness opinion and associated risks, if any. Please also quantify the value of the warrants issued and explain how the
$10.00 conversion price was determined.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Response</I>: <FONT STYLE="font-weight: normal">In
response to the Staff&rsquo;s Comment, the Company revised its disclosure on pages 45 and 128 to discuss the reasoning for the
determination by ApolloMed not to provide an updated fairness opinion and the reasoning for the determination by NMM not to request
an updated fairness opinion for either Amendment No. 1 or Amendment No. 2 to the Merger Agreement. In addition, the Company revised
its disclosure on page 22 to quantify the value of the warrants to be issued to NMM shareholders in the proposed merger and the
Company revised its disclosure on page 170 to explain how the $10.00 conversion price of the Alliance note was determined.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Questions and Answers for ApolloMed
Stockholders, page 17</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><U>Q:</U></TD><TD STYLE="text-align: justify"><U>What will I receive in the Merger, page&nbsp;17</U></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">We note your disclosure that ApolloMed stockholders will experience significant dilution as a result
of the issuance of ApolloMed common stock and warrants to the NMM shareholders in connection with the Merger. Please revise this
Q&amp;A to quantify the percentage ownership that ApolloMed stockholders will have in the Company after the Merger, both initially
and assuming exercise of the warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><U>Q:</U></TD><TD STYLE="text-align: justify"><U>What interests do ApolloMed&rsquo;s current executive officers and directors have in the Merger,
page&nbsp;19</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">We note your disclosure that in conjunction with the Merger, Warren Hosseinion, the Chief Executive
Officer of Apollo Medical Holdings, Inc., and the sole shareholder of Maverick Medical Group, Inc. (&ldquo;MMG&rdquo;), will sell
to APC-LSMA all the issued and outstanding shares of capital stock of MMG. Please revise to quantify the interests of directors,
executive officers, and affiliates. Please refer to Item 18(a)(5)(i) of Form S-4 and Item 5 of Schedule 14A and revise here and
on pages 31 and 151.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company has revised its disclosure on pages 20, 24, 31-32, 62, 120, 154
and 155.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Questions and Answers for NMM Shareholders,
page 22</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><U>Q:</U></TD><TD STYLE="text-align: justify"><U>What will I receive in the Merger, page 22</U></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">We note your disclosure that pursuant to the Merger Agreement, NMM common stock will be converted
into the right to receive shares that represent 82% of the total issued and outstanding shares of ApolloMed common stock and warrants
to purchase a pro-rata portion of an aggregate of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share.
Please quantify, to the extent possible, the total value of the interest in ApolloMed that NMM shareholders will receive as a result
of the Merger.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Respons</I></B>e:
In response to the Staff&rsquo;s Comment, the disclosure in Amendment No. 1 has been revised on page 22.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><U>Q:</U></TD><TD STYLE="text-align: justify"><U>Is the transaction expected to be taxable to NMM shareholders,
page 25</U></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">We note your disclosure throughout that NMM and ApolloMed &ldquo;expect&rdquo; or &ldquo;intend&rdquo;
that the Merger will qualify as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Internal Revenue Code
of 1986. Please revise throughout to provide unequivocal disclosure of what the tax consequences will be, or alternatively, revise
to explain the degree of uncertainty. See Staff Legal Bulletin No. 19.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the disclosure in Amendment No. 1 has been revised on pages 25, 36, 48, 107, 151
and 219 to provide disclosure of what the tax consequences will be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risk Factors</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The actual exchange ratio at the
closing might not be consistent with the assumed exchange ratio which BofA Merrill Lynch based its fairness opinion, page 45</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">We note your disclosure that the actual exchange ratio at the closing might not be consistent with
the exchange ratio on which BofA Merrill Lynch based its fairness opinion because the number of shares of ApolloMed&rsquo;s common
stock issued and outstanding at the closing may not be the same as that used by BofA Merrill Lynch as the basis of its fairness
opinion. Please revise to clarify how, if at all, the number of issued and outstanding shares of ApolloMed&rsquo;s common stock
has changed since BofA Merrill Lynch&rsquo;s December 21, 2016 opinion and the impact of that change on the exchange ratio.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the disclosure in Amendment No. 1 has been revised on page 45.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>NMM&rsquo;s operations are dependent
on a limited number of key payors, page 83</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">Please identify the HMO&rsquo;s upon whom NMM&rsquo;s operations are dependent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I></B>: In response
to the Staff&rsquo;s Comment, the disclosure in Amendment No. 1 has been revised on page 83.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Background of the Merger between
ApolloMed and NMM, page 121</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">On page 121 you state that &ldquo;ApolloMed management has had multiple interactions with different
parties, including NMM&rdquo; and that the subsequent discussion is a record of &ldquo;certain material events&rdquo; leading up
to the Merger Agreement. Please confirm that the disclosure includes material discussions with all parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
The Company supplementally confirms that the disclosure includes all material discussions with all parties and in response the
Company has made a clarifying revision on page 121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">Please disclose the outside general counsel that advised ApolloMed on the legal considerations
of the transaction prior to the engagement of McDermott Will &amp; Emery LLP. Please also identify NMM&rsquo;s legal counsel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company has revised its disclosure on pages 123 and 125.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Opinion of ApolloMed&rsquo;s Financial
Advisor, page 132</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">Please revise the Selected Publicly Traded Companies Analysis on page 134 to explain the selection
criteria BofA Merrill Lynch utilized to select the companies identified. If any companies fit the selection criteria but were excluded
from the analysis, please explain the reason(s) for the exclusion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In Amendment No. 1, the disclosure on page 134 of the joint proxy statement/prospectus has been revised to clarify the selection
criteria for the selected companies included in BofA Merrill Lynch's analyses of the Company. The Company advises the Staff that
BofA Merrill Lynch believes that the selected companies included in its analyses reflect the companies that in BofA Merrill Lynch's
professional judgment fit its selection criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">We understand that the discounted cash flow analysis is based on the ApolloMed and NMM forecasts.
Please revise to describe these forecasts or advise us why you believe the forecasts are not necessary for shareholders to appropriately
evaluate the discounted cash flow analysis. Please also revise the discussion of Vantage Point&rsquo;s opinion, which similarly
appears to rely on management projections and/or forecasts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:&nbsp;
The Company respectfully submits that the inclusion in the Registration Statement of the forecasts and projections will not enhance
stockholders' understanding of the discounted cash flow analysis or the summary discussion of either the BofA Merrill Lynch fairness
opinion or the Vantage Point fairness opinion. Moreover, the forecasts and projections were generated solely in connection with
the proposed merger and were not created with a view to disclosure. The Company believes that inclusion in the Registration Statement
of the details of the forecasts and projections would overstate the relevance of these forecasts and projections, particularly
given the passage of time, and could be potentially misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Opinion of NMM&rsquo;s Financial
Advisor, page 138</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">In your discussion of the Selected Public Companies Analysis, please state if there were any companies
that fit your selection criteria but were excluded from the analyses. Please explain the reason(s) for the exclusion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
NMM was informed by its financial advisor that there were no companies that fit its selection criteria that were excluded from
the analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Unaudited Pro Forma Condensed Combined
Financial Statements</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Notes to Unaudited Pro Forma Condensed
Combined Financial Statements</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Fair Value of the ApolloMed&rsquo;s
preferred shares held by NMM, page 176</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">We note that the registrant&rsquo;s series A and series B preferred stock had a historical value
of $10,962,523 and liquidation preferences of $14,999,994 at March 31, 2017. We note the fair value of the preferred stock, for
purposes of calculating the purchase price, is $20,784,000 and is reflective of the liquidation preferences, claims of priority
and conversion option values thereof. Please revise to enhance your disclosure to provide the calculations used to determine this
fair value.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 180.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>MMG transaction, page 177</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">Please revise your disclosure to clarify the amount and nature of consideration to be paid by APC-LSMA
for the shares of MMG. Please clarify for us where this consideration is reflected in the preliminary purchase consideration.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I></B>: In response
to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 181. The $100 consideration is not reflected in the
preliminary purchase consideration as the amount is immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Potential Payments upon Termination
or Change-In-Control, page 196</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">Please revise this section, or the Employment Agreements discussion cross-referenced, to quantify
potential payments and benefits, as contemplated by Item 402(j)(2) of Regulation S-K and Instruction 1 to Item 402(j).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company directs the Staff&rsquo;s attention to the section of Amendment No. 1 titled
&ldquo;Merger-Related Compensation for ApolloMed&rsquo;s Named Officers&rdquo; on page 153.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Principal Stockholders of ApolloMed,
page 201</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Principal Shareholders of NMM,
page 203</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">Please identify the names of the natural persons who, directly or indirectly, have or share voting
and/or investment power with respect to the shares held by legal entities, such as Network Medical Management, Inc., NNA of Nevada,
Inc. and Allied Physicians of California, as required by Item 18(a)(5)(ii) of Form S-4. See also Item 6(d) of Schedule 14A and
Instruction 2 to Item 403 of Regulation S-K.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company has revised its disclosure on pages 206 and 207.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Certain Material U.S. Federal Income
Tax Consequences of the Merger, page 214</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify">Please revise to reference the tax opinion you will receive from McDermott Will &amp; Emery, currently
referenced as exhibit 8.1 in the Exhibit Index.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Response</I></B>:
In response to the Staff&rsquo;s Comment, the Company has revised its disclosure on page 219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Network Medical Management Inc.</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Notes to Consolidated Financial
Statements</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><U>1.</U></TD><TD STYLE="text-align: justify"><U>Description of Business, page F-12</U></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify">Please tell us how you determined that APC is the primary beneficiary of APC-LSMA. Within your
response, please address the fact that APC-LSMA is solely owned by Dr. Thomas Lam and reference the authoritative accounting literature
management relied upon.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B><I>Response</I></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The following
analysis based on consolidation guidance (ASC 810) supports the determination that APC is the primary beneficiary of APC-LSMA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&bull;&#9;Does
the VIE consolidation guidance apply? &ndash; None of the scope exceptions apply since APC was solely involved in the design of
APC-LSMA. The APC Board of Directors nominated Dr. Lam as the sole shareholder of APC-LSMA in order to provide APC with a vehicle
to acquire ownership interest in other professional medical corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&bull;&#9;Does
APC hold a variable interest in APC-LSMA?- APC-LSMA&rsquo;s sole function is to act as the nominee shareholder for APC in other
California medical professional corporations in which APC, by law, cannot be the shareholder. The reason for this is that California
Business &amp; Professions Code, section 2408 does not permit a professional corporation to have shareholders who are not licensed
natural persons, with the exception of another professional corporation that has only one shareholder. Due to the foregoing restriction,
APC is unable to hold shares in other professional corporations by reason of APC having more than one shareholder. For this sole
reason, APC-LSMA was organized by APC, with Dr. Thomas Lam designated by APC as APC-LSMA&rsquo;s sole nominee shareholder. Dr.
Lam is also the Chief Executive Officer and a director of NMM, and the Chief Executive and Financial Officer and a director of
APC, and is a significant shareholder in both APC and NMM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&bull;&#9;APC-LSMA
has no bank accounts and all investments and loans made by APC-LSMA are funded directly by APC. APC-LSMA has no other operating
activities other than being an investment vehicle for APC. When the various investees make distributions, they are made directly
to APC and not to APC-LSMA or Dr. Lam. Dr. Lam is only a nominee of APC and does not receive any additional compensation for this
role. Given that there are no bank accounts and all the financial transactions are directly handled by APC, APC has both an explicit
and an implicit variable interest in APC-LSMA. Given that APC-LSMA is essentially a conduit for the investments made by APC and
has no employees, operations or bank accounts, APC is exposed to the entire risks and rewards of the investments made through APC-LSMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&bull;&#9;Is
APC-LSMA a VIE? &ndash; APC-LSMA has no bank accounts, employees or operations and relies entirely on APC, to fund its investments.
Its sole function is to hold investments on behalf of APC. Dr. Lam has not made any investments in APC-LSMA from his personal funds
and does not receive nor is he entitled to any distributions or additional compensation for being the nominee shareholder of APC-LSMA.
All the distributions from investees are paid to APC. Therefore, the total equity at risk is not sufficient to permit APC-LSMA
to finance its activities without additional subordinated financial support from APC and therefore APC-LSMA is a VIE. In addition
Dr. Lam, the sole shareholder of APC-LSMA does not control the entity and all decisions are made by APC&rsquo;s Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&bull;&#9;Who is the primary beneficiary of APC-LSMA? - APC makes all the investments on behalf of APC-LSMA
and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits
from all the investments made by APC-LSMA. Dr. Lam does not receive any additional benefit or compensation for his nominee ownership
in APC-LSMA. Dr. Lam is also not exposed to any risks and rewards of the ownership of APC-LSMA. Dr. Lam is only a nominee shareholder
of APC-LSMA. Dr. Lam is the Chief Executive Officer and a director of NMM, and the Chief Executive and Financial Officer and a
director of APC, and is a significant shareholder in both APC and NMM. As such, Dr. Lam has a fiduciary duty to act on behalf of
APC in performing his duties at APC-LSMA. In the event that Dr. Lam severs ties with APC, the APC Board members will designate
a new nominee shareholder for APC-LSMA and transfer shares between the two parties. The power of APC over APC-LSMA is based on
the fact that the APC Board nominated Dr. Lam as the shareholder of APC-LSMA and all decisions related to APC-LSMA are made at
meetings of the APC Board of Directors. APC directly funds all acquisitions of APC-LSMA which has no bank account or employees.
The APC&rsquo;s board retains unrestricted power to change the nominee shareholder of APC-LSMA at any time for any reason. Accordingly,
APC is the Primary Beneficiary of APC-LSMA.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, as both
power and economics are present, APC (the reporting enterprise) is considered the primary beneficiary and should consolidate APC-LSMA
(the VIE).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Exhibits</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify">Please file all remaining exhibits as soon as possible. Upon review, we may have further comments.
If you are not prepared to file the legal and tax opinions with your next amendment, please file draft opinions as correspondence
for us to review.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Response</I></B>: The
Company acknowledges the Staff's comment and has filed remaining exhibits with Amendment No. 1 other than the legal and tax opinions,
draft forms of which are attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should you have any
questions concerning any of the foregoing, please contact me by telephone at (650) 815-7438.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Mark J. Mihanovic</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mark J. Mihanovic</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">McDermott Will &amp; Emery LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B STYLE="font-style: normal; font-weight: normal">Cc:</B></TD><TD STYLE="text-align: justify"><B STYLE="font-style: normal; font-weight: normal">Warren
                                         Hosseinion Apollo Medical Holdings, Inc.</B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 208px; height: 73px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Boston&nbsp;&nbsp;&nbsp;Brussels&nbsp;&nbsp;&nbsp;Chicago&nbsp;&nbsp;&nbsp;Dallas&nbsp;&nbsp;&nbsp;D&uuml;sseldorf&nbsp;&nbsp;&nbsp;
Frankfurt&nbsp;&nbsp;&nbsp;Houston&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;Los Angeles&nbsp;&nbsp;&nbsp;Miami</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Milan&nbsp;&nbsp;&nbsp;Munich&nbsp;&nbsp;&nbsp;New
York&nbsp;&nbsp;&nbsp;Orange County&nbsp;&nbsp;&nbsp;Paris&nbsp;&nbsp;&nbsp;Rome&nbsp;&nbsp;&nbsp;Seoul&nbsp;&nbsp;&nbsp;Silicon
Valley&nbsp;&nbsp;&nbsp;Washington, D.C.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 8pt">Strategic alliance with MWE China Law Offices (Shanghai)</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">700 North Brand Blvd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 1400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glendale CA 91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Apollo Medical Holdings, Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Registration Statement on Form S-4 (File
No. 333-219898)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as special counsel to Apollo
Medical Holdings, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), &nbsp;in connection with its registration statement
on Form&nbsp;S-4, as amended (the &ldquo;Registration Statement&rdquo;), filed with the Securities and Exchange Commission under
the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) relating to the proposed public offering of up to 40,390,879
shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;) of the Company (the &ldquo;Shares&rdquo;)
in connection with the merger (the &ldquo;Merger&rdquo;) contemplated by the Agreement and Plan of Merger, dated as of December
21, 2016 by and among the Company, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of the Company
(&ldquo;Merger Subsidiary&rdquo;), Network Medical Management, Inc., a California corporation (&ldquo;NMM&rdquo;), and Kenneth
Sim, M.D., in his capacity as the representative of the shareholders of NMM, as amended (the &ldquo;Merger Agreement&rdquo;).
The Shares consist of up to (a) up to 38,640,879 shares of Common Stock of the Company (the &ldquo;Merger Shares&rdquo;); (b)
warrants to purchase 850,000 shares of Common Stock; (c) warrants to purchase 900,000 shares of Common Stock ((b) and (c), the
&ldquo;Warrants&rdquo;); and (d)&nbsp;up to 1,750,000 shares of Common Stock issuable upon exercise of the Warrants (the &ldquo;Warrant
Shares&rdquo;), in each case as contemplated by and in accordance with the terms and conditions of the Merger Agreement. This
opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item&nbsp;601(b)(5) of Regulation
S-K, 17 C.F.R. &sect; 229.601(b)(5), in connection with the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have examined and relied upon the originals
or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates
of officers or representatives of the Company and others, and such other documents, certificates and corporate and other records
as we have deemed necessary or appropriate as a basis for the opinions set forth herein. In our examination, we have assumed the
legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as
originals, the conformity to the original documents of all documents submitted to us as copies, and the authenticity of the originals
of such copies, and the accuracy of the English translations. As to any facts material to the opinions expressed herein which we
did not independently establish or verify, we have relied on representations and statements of fact made in the documents so reviewed
and upon statements and representations of officers and other representatives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0"> ___________, 2017</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not express any opinion as to the
laws of any jurisdiction other than the General Corporation Law of the State of Delaware. No opinion is expressed herein with respect
to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the opinions expressed
below, we have assumed that, at and prior to the time of the issuance and delivery of any Shares by the Company pursuant to the
Registration Statement, (i) the Registration Statement has been declared effective and no stop order suspending the effectiveness
of the Registration Statement has been issued and no proceedings with respect thereto have been commenced or threatened, (ii) the
total number of Shares issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then
authorized to issue under its Certificate of Incorporation then in effect, (iii) all relevant corporate actions heretofore taken
by the Company remain in full force and effect, (iv) the Merger Agreement governing the Merger has been duly adopted and the Merger
has been duly approved by all necessary corporate action of the Company, Merger Subsidiary and NMM, (v) there has not occurred
any change in law materially adversely affecting the power of the Company to issue and deliver the Shares or the validity of such
Shares, and (vi) the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the
General Corporation Law of the State of Delaware.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon the foregoing and subject to
the assumptions and qualifications set forth herein, we are of the opinion that</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Merger
Shares and the Warrants have each been duly authorized;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Merger Shares following (i)&nbsp;effectiveness of the Registration Statement, (ii)&nbsp;effectiveness of the Merger pursuant to
the Merger Agreement, and (iii)&nbsp;issuance of the Merger Shares pursuant to, as contemplated by, and subject to the terms and
conditions of, the Merger Agreement, will be validly issued, fully paid, and nonassessable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
Warrant, when issued and sold by the Company and delivered by the Company in accordance with and in the manner described in the
Registration Statement, the Merger Agreement, and the Warrant, when executed and delivered by the Company, will constitute the
valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable
bankruptcy, insolvency, fraudulent conveyance, moratorium and similar laws affecting creditors&rsquo; rights generally and equitable
principles of general applicability; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">___________, 2017</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Warrant Shares following (i)&nbsp;effectiveness of the Registration Statement, (ii)&nbsp;effectiveness of the Merger pursuant to
the Merger Agreement, (iii)&nbsp;due exercise of the applicable Warrants in accordance with the terms of the&nbsp;Warrants, and
(iv)&nbsp;issuance of the Warrant Shares pursuant to, as contemplated by, and subject to the terms and conditions of, the&nbsp;Merger
Agreement and Warrants, will be validly issued, fully paid, and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinions expressed above are subject
to the following assumptions, qualifications, and limitations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This opinion
is subject to the effect of applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium, and similar laws
affecting the enforcement of creditors&rsquo; rights generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This opinion
is subject to the effect of general principals of equity (regardless of whether considered in a proceeding in equity or at law),
which may, among other things, deny rights of specific performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We express
no opinion as to the enforceability of any provisions contained in the Warrants that (i) purport to excuse a party for liability
for its own acts, (ii) purport to make void any act done in contravention thereof, (iii) purport to authorize a party to act in
its sole discretion or provide that determination by a party is conclusive, (iv) require waivers or amendments to be made only
in writing, or (v) purport to effect waivers of constitutional, statutory or equitable rights or the effect of applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not
express any opinion as to the enforceability of provisions of the Warrants purporting to require a party thereto to pay or reimburse
attorneys&rsquo; fees incurred by another party, or to indemnify another party therefore, which provisions may be limited by applicable
statutes and decisions relating to the collection and award of attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not
express any opinion as to the enforceability of provisions relating to evidentiary standards or other standards by which the Warrants
are to be construed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not
express any opinion as to the enforceability of severability provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect
to the opinion expressed in paragraph (c) above, we are assuming that the Warrants have been executed in the form reviewed by us
and have not been terminated or amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">___________, 2017</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"> </TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing of this
opinion letter as an exhibit to the Registration Statement and to the reference to our Firm under the caption &ldquo;Legal Matters&rdquo;
in the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose
consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This opinion letter is limited to the matters
expressly set forth herein and no opinion is implied or may be inferred beyond the matters expressly so stated. This opinion letter
is given as of the date hereof and we do not undertake any liability or responsibility to inform you of any change in circumstances
occurring, or additional information becoming available to us, after the date hereof which might alter the opinions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%; padding: 0; text-indent: 0">Very respectfully yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">McDermott Will &amp; Emery LLP</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Boston&nbsp;&nbsp;&nbsp;Brussels&nbsp;&nbsp;&nbsp;Chicago&nbsp;&nbsp;&nbsp;Dallas&nbsp;&nbsp;&nbsp;D&uuml;sseldorf&nbsp;&nbsp;&nbsp;Frankfurt&nbsp;&nbsp;&nbsp;Houston&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;Miami</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Milan&nbsp;&nbsp;&nbsp;Munich&nbsp;&nbsp;&nbsp;New
York&nbsp;&nbsp;&nbsp;Orange County&nbsp;&nbsp;&nbsp;Paris&nbsp;&nbsp;&nbsp;Rome&nbsp;&nbsp;&nbsp;Seoul&nbsp;&nbsp;&nbsp;Silicon
Valley&nbsp;&nbsp;&nbsp;Washington, D.C.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 8pt">Strategic alliance with MWE China Law Offices (Shanghai)</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">700 N. Brand Boulevard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 1400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glendale, California 91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="padding-right: 5.75pt">Apollo Medical Holdings, Inc./Network Medical Management, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel to Apollo Medical Holdings, Inc., a
Delaware corporation (&ldquo;ApolloMed&rdquo;) in connection with the merger (the &ldquo;Merger&rdquo;) of Apollo Acquisition Corp.,
a California corporation (&ldquo;Merger Sub&rdquo;) and wholly-owned subsidiary of ApolloMed with and into Network Medical Management,
Inc., a California corporation (&ldquo;NMM&rdquo;), pursuant to an Agreement and Plan of Merger by and among ApolloMed, Merger
Sub, and NMM dated as of December 31, 2016, and amended on March 30, 2017 and October 17, 2017 (the &ldquo;Merger Agreement&rdquo;).
Capitalized terms not otherwise defined herein shall have the meanings set forth in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In formulating this opinion, we have examined the Merger Agreement,
the Registration Statement on Form S-4 of ApolloMed (the &ldquo;Registration Statement&rdquo;), and the Proxy Statement/Prospectus
relating to the Merger Agreement included therein (the &ldquo;Proxy Statement&rdquo;), as filed with the Securities and Exchange
Commission on August 10, 2017, as amended through the date hereof, and such other documents as we deem relevant for purposes of
this opinion. In addition, we have assumed with your consent that (i) the Merger will be consummated in the manner contemplated
by the Registration Statement and the Proxy Statement and in accordance with the provisions of the Merger Agreement and none of
the terms and conditions contained therein have been or will be modified in any respect relevant to this opinion; (ii) the statements
concerning the Merger, other than those relating to the U.S. federal income tax consequences of the Merger, set forth in the Registration
Statement and the Proxy Statement, including the purposes of the parties for consummating the Merger, are true, accurate and complete
and will continue to be true, accurate and complete through and as of the Effective Time; (iii) the representations made to us
by ApolloMed and NMM in connection with the Merger (in the form of representation letters dated as of the date hereof (the &ldquo;Representation
Letters&rdquo;)) and delivered to us for purposes of this opinion are true, accurate and complete and will continue to be true,
accurate and complete through and as of the Effective Time; (iv) any representation or other statement in the Representation Letters
or the other documents referred to herein made &ldquo;to the best of the knowledge&rdquo; or similarly qualified is, and thereafter
as relevant will be, in each case, correct without such qualification; (v) no actions have been (or will be) taken that are inconsistent
with any representation or other statement contained in the Representation Letters; (vi) each of ApolloMed, Merger Sub and NMM
will comply with all reporting obligations with respect to the Merger required under the Internal Revenue Code of 1986, as amended
(the &ldquo;Code&rdquo;); (vii) the Merger Agreement constitutes the legal, valid and binding obligation of the parties thereto
and is enforceable in accordance with its terms; (viii) there are no other understandings or agreements between or among the parties
to the Merger Agreement that bear directly or indirectly on the Merger; and (ix) original documents (including signatures) are
authentic, documents submitted to us as copies conform to the original documents, and there has been (or will be by the Effective
Time) due execution and delivery of all documents where due execution and delivery are prerequisites to the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">___________, 2017</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"> <!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In rendering this opinion, with your permission, we have not
undertaken any independent investigation or verification of any fact or matter set forth in any documents or materials or any assumption
upon which we have relied (including, without limitation, the assumptions set forth above), and we expressly disclaim any intent,
undertaking, or obligation to make any such investigation or verification. We are not aware, however, of any material facts or
circumstances contrary to or inconsistent with any fact or matter set forth in any documents or materials or any assumption upon
which we have relied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing and subject to the exceptions, qualifications
and limitations set forth herein, we are of the opinion that (i) for United States federal income tax purposes, the Merger will
qualify as a reorganization within the meaning of Section 368(a) of the Code, and that each of ApolloMed, Merger Sub and NMM will
be a party to such reorganization within the meaning of Section 368(b) of the Code; and (ii) the discussion contained in the Proxy
Statement under the caption &ldquo;Certain Material U.S. Federal Income Tax Consequences of the Merger&rdquo; concerning the federal
income tax consequences of the Merger to the NMM shareholders, insofar as it summarizes United States federal income tax law, is
correct in all material respects as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This opinion relates solely to the United States federal income
tax consequences of the Merger and no opinion is expressed as to federal tax consequences of the Merger, other than those related
to United States federal income taxes, or the tax consequences of the Merger under any foreign, state or local tax law. This opinion
is based on current United States federal income tax law and administrative practice in effect as of the date hereof. It represents
our best legal judgment as to the matters addressed herein, but is not binding on the Internal Revenue Service (&ldquo;IRS&rdquo;)
or the courts. No ruling has been or will be sought from the IRS as to any United States federal income tax consequences of the
Merger. Accordingly, no assurance can be given that this opinion, if contested, would be sustained by a court. Furthermore, the
authorities on which we rely are subject to change either prospectively or retroactively, and any such change, or any variation
or difference in the facts from those on which we rely and assume as correct, as set forth above, might affect the conclusions
stated herein. Nevertheless, by rendering this opinion, we undertake no responsibility to advise you as to any changes or new developments
in United States federal income tax laws or the application or interpretation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the filing of this opinion as an exhibit
to the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose
consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">McDermott Will &amp; Emery LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ *@# 2(  A$! Q$!_\0
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M->./"/C>(82&<6MTP'5,YQ^*M(*]$\70QZSI]KH&\^7J\GE2E&P?(52[D'W
M"_\  ZSOBQH/_"0_#;5[9$W3P1_:H?7='\QQ]5W#\:R/A'JTOBG1+'59]Y_L
MZQ7306'WI0<R,/7*K#SZYH R_@7J$^GQ:[X+OV_TO1[MB@/="2&Q[;AG_@==
MWI4JOJOB'77CED59!9Q".,NQC@!W;0.3^\>08'I7FGCJ<_#SXT:9XM2-S8ZM
M;M!=)&,EG "X_P#11_ UZ[X=T]]+\/V-I-S.D8:8YZRM\SG\6+&@#EOAQ)X1
MDN?$!\+V5W;2?:Q]N^THR$R?-\H#'( .[C QFLWP/_R6/XA_[UI_Z :=\,/^
M1N^(7_89/_LU-\#_ /)8_B'_ +UI_P"@&@!VD_\ )P_B#_L#1?\ H25U_C2Z
MU*Q\%:S=:0"=0BM'>':,D$#J!W(&2/<5R&D_\G#^(/\ L#1?^A)6IXLUB2;Q
MKX>\)&X:UM-266:YD1MKS*@R(5;MN/7'.!@8S0!B^'K^VO=1\.:AX:O;HV M
MFEUNXN+AGB(*?*LA<X,V_P!.0,YX(KTNWOK2[9EMKJ"9E&6$<@8CZXKR6_5/
MA/XDFB-G]H\%ZX6VVVT,EK=8^Y@\!7QWX_[YY[_P9X2T_P (Z##:6EI!%<.N
M^YDC49DD/)YZD D@#L,4 ><_':1(M:\#2R,%1-09F8]  T637H:^-='N_$.G
M:-I]Y;WD]V)&<1OGRT5"<_B<#\:\^^.9 U[P'SC_ (F+'_QZ*O6;K3(+O4;"
M^DR)K)G:(C'\:E2#[<_H* ,ZYN=-\"^%4/D7;:=8IM"P1-,R( 3D@?P@#KT%
M9D?Q(TN\TF+4=,T[5M3A:(32"RM@YA!&</\ ,!NQ_""3[4NKZ]!K/ASQM;0*
MIBTV">U:4-D._D;F'M@MCZ@TWX4(J?"WP^%4*#;9.!C)+')H L6_Q T;4=-M
M[S1TO-6:>/S!;V,.Z1%R0=X) 3D$?,1G'&:O^&?%6F>*[*:YTXS*UO*8;BWN
M(S'+!(.JNIZ&N.^!D44?@.X9(T5GU*XW$#!." ,_A6'HLEW#%\8'L=PN4N)F
MBV]0VR3D>] 'H9\:6<L-W<Z?8:AJ5G:,R375I$K)E?O!,L#)COM!_$TZ]\<:
M)9>%H_$@EGNM+D3>LUK \O'<G ^7&,'=C!ZUR_PKT2UO?AEHD\6H:E&&A8,D
M-XZ*&#L&P >.<U?U[PYI?A7X2^)-,T>)HK5;*Y?8TK/AF0YY8DCZ>] %B7XG
M^'XHM/N E])9WKQ1_:X[?,,,D@#*CMGAL$9 SCO5W_A/-)_X2H>&C#J U0G(
MB-HX!3.-X;H4]Z@^&EK OPP\.QB)-ALXY-I7C<?F)^N3FL3XLV%QI\.E>.-,
MC+7V@3AY57K+;,<.I_/\ 6H Z_6_$UIH%Q:0W5M?RM=OY<)MK9I0SX)V\=#A
M2?H#16?I-];^*O$*:O:N)=-L;95MG'1II5#,?JL91?\ @;"B@#J6571D8!E8
M8(/0BL;PIX9LO"'A^#1K NT$3.^Y\;F+,6YQ]<?0"MJB@#$\2>%K#Q0FG+?!
MO] O8[R/;CED/W3G^$]#6O<1--;R1)-)"S*0)(\;E]QD$9^H-244 <GH'@*U
M\.:CJ%]9:QJS2Z@[2W0FDC=9)#GY\;."-Q/''3MQ1HO@.UT/Q%>:Y;ZOJLMY
M?$&[$TD;)-CID!!C&>,8KK** .1M/ %M9^*Y?$J:UJ[:E,@CE9Y(BDD8Q\A7
MR\8^4=,'WJYXM\%Z7XQM;=+YIX+FTD\VUO+5]DL#^JG\!Q[#TKHJ* .0;X?6
M6HZ?):>(]1O]>#H44WC*HB_VD5  '_VCD^_)JQX?\'R:%) )/$.K:A;6JE;6
MWNI%VQC&.2J@O@<#<2!Z5T]% '#^)OA?IGBZ_AN]7U?6)&MV9K=(YHT6')S\
MH">PY.3P*U9?"MU-;&!O%>OA2NTLDD*O_P!]"+(/O71T4 <;IWPWTK2?"E]X
M=L;_ %.*UOI7EN9?.4RR;U"LNXKT('IGWK1T3PE%X?\ #AT.PU74EME&V&1W
MC:2 9SA3LQZ]0?:NAHH YCPKX(L_!VG7-AIFHZBUO.6<+/(C^6YZNIV=>G7(
M]J9X=\"6?AK5K[4;35-3FDOY#+=I<2(R3.<_,0$!!Y/0BNJHH Y.Q\$#1)IQ
MX?UB\TNRN)#*]DB1R1(QZF/>I*9]!Q[5:OO!ME>^')M#%Y?6]M<%S=212+YM
MR7^\79E.<]\8].G%=%10!C^&_#T7AC2H],MKZ\N;6%0D*W3*QC4=@54<?7-2
M>([NRLO#U_+J*+);&%D:%CCSMPP(QZELX ]ZU*X'Q%86VH_%KPNEY&9H[>VG
MN(HV8[5E4C:^W.,CUH Z#P9X=B\*^$=.T>-0&@B'FD<YD/S.<]^2:*WJ* /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "' 8$# 2(  A$! Q$!_\0
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M^4?B<#\:-"O)=1\/Z;?3[?.N;6*9]HP-S("<?B:+.UPYES<IH4444AA1110
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MHMXB:YGT+NG3W5Q812WUF+.Y8'? )1)LY_O#@\8/XU:HHKD.]!1110 4444
M%<EX+8-J?BH#MJ[_ /H"UT.IZI9:/827M_<)!!&,EG/7V'J?:O+?AGXSLI_$
M6N07<BV[:E=&ZM_,. 22<IGUQC'K@UK"#<)-&%2I&-2";[_D>LW-O%>6LUM.
M@>&9#&ZGH5(P17R[J5I>>#?&$L*,5N+"X#Q.?X@#E3^(Q^=?4]>0_&OP]NBM
M/$$"<I_H]Q@=CRA_/(_$5KA9VERO9F..I\T.=;HZ77-7C\5:/HFEV#D#72'F
MVGF.W7#2Y/8Y^7\37;QQI%&L<:A40!54#@ =J\O^#.BRQZ3+K5R68RYM[4,?
MN1!B6Q[%R?\ OFO4JRJI1?(NAM0;G'VDMW_7_!/(_CI_QYZ+_P!=)OY+5CX'
M?\@35?\ KY7_ -!K-^.5["]QH]DDBF:(2R2(#RH;:%S]<&K'P.O81;ZM8F11
M-O254)Y9<$$CZ<?F*Z&G]6_KN<B:^N_UV.H^+(<_#R^V]!)$6^F\?UQ7+? N
M1?+UR/\ BS"WX?/7I^N:5%KFB7FF3'"7,13=_=/8_@<'\*\.\#W\W@'Q[+IV
MM+]GBF'V>9F^Z.<H^?[OOZ&II>]1E!;FE;W,1"H]MCZ!HI%8,H92"",@CO67
MXBUN/0M(ENB ]PW[NV@'+32GA5 ZG)_2N5)MV1VMI*[-6O(_CI_QZ:)_OS?R
M2O5+$W1L+<WWEB[,:F81#"A\<XY/&:\A^.5["]QH]DDBM-$LLDB \J&VA<_7
M!_*ML.OWJ.;%O]PS2^!Q_P")%J@_Z>5_]!KU2O'_ ('7\"Q:K8-*JSLZ2HA/
M+#!!(^G'YU[!2Q"_>,>$=Z,0KCOB?JZ:3X&OEW 37@^S1CUW?>_\=W5N:QXE
MT;08&EU+4((2!D1ELNWT4<FO$]:NM<^*WB-%TRSD6P@.R+?PD0/5G;ID^@],
M#-.C3O+F>R%B:RC%PCK)E?X3Z(^J^,X;ID)M[ &=SVW=$'USS_P$UVGQQ5_[
M%TIAG8+AP?KMX_K7;^$?"UIX2T5+&W/F2L=\\Q&#(_K[ =A4/CGPV?%/A>XL
M(\"Y4B6W)Z;UZ#\02/QJW64JRET1G'#..'<.K,+X-R*_@7:.L=U(I^N%/]:]
M!KQ?X0:V-'U6_P##>I9MII9-\22_*1*.&7ZD8Q]*]HK/$1M49MA9*5)>6@45
M@ZUXA-CJ=AI.GQ)=:E=R#,1/$,(^](V.@ Z>IK>K)II79NI)MI=#Y\\9_P#)
M:&_Z_+7_ -!CKZ#KYV\974)^,$UQYB^5'>6^Y\\#:$#?D0?RKZ)!!&0<BNG$
M?##T./"?'4]0KE/B5_R3S6/^N:_^AK75UR/Q.F2'X>:KO8 NJ(H)ZDNO K"G
M\:]3IK?PY>C.6^!O_()U?_KNG_H)KU>O)/@9,GV'6(=P\P21OMSSC!&?TKUN
MKQ'\5F6$_@Q/!OC9_P CC9_]>"?^AO7N-A_R#K;_ *Y)_(5X3\:9DD\:P(C
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M_$;QIH%^=.NK+3[*5D#I)&IDW*<C()..H/45ZOH-S->^'=,NKA]\\]I%)(V
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M9/1H[>BBBL#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX'&?F-51A&<N61&(J3IPYHV/9-)U.#6=*MM1M0X@N$WIO&#CW%37W_(/N?\
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M55& !V%<AX4OHA=M#<,3,4"0LQX"@YVBNQH **,YHH ^4/$O_(U:Q_U_3?\
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L0O\ #M\V[8G\(SZG))_#THHKH<K44EU.6,4\0V^B5CO:***YSJ"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
